First-line systemic treatment options for Advanced Hepatocellular Carcinoma | IPSEN ESMO Symposium 2020 (Virtual) | 2020-09-01 |
Immune Checkpoint Inhibitor for Hepatocellular Carcinoma | Multi-specialty Medical Mega Conference, Hong Kong | 2020-09-01 |
Immunotherapy for Hepatocellular Carcinoma: Current and Future | 50th Annual Meeting of The Gastroenterological Society of Taiwan and 29th Annual Meeting of The Digestive Endoscopy Society of Taiwan, Taipei, Taiwan(Virtual meeting ) | 2020-07-01 |
The Implication of CheckMate 459 in Liver Cancer | The First Big Bay Area Hepatobiliary Cancer Forum organised by National Cancer Center China, Shenzhen, China | 2019-12-01 |
Update on Medical Treatment for Advanced Hepatocellular Carcinoma | ESMO Preceptorship on Gastrointestinal Tumours, Singapore | 2019-11-01 |
First-line systemic treatment options | IPSEN ESMO Asia Symposium 2019, Singapore | 2019-11-01 |
Richard Yu Lecture | Hong Kong College of Physicians and Royal College of Physicians Joint Scientific Meeting, Hong Kong | 2019-10-01 |
Defining the Right Treatment for the Right Patients: the perspective in Asian HCC treatment and HK experiences | Ipsen Taipei Launch Symposium, Taipei, Taiwan | 2019-10-01 |
Emerging Clinical Data with Immuno-oncology for HCC | King Chulalongkorn Hospital, Bangkok, Thailand | 2019-10-01 |
Maximize therapeutic benefits of systemic treatment in HCC management in second line and beyond | National Cheng Kung University Hospital, Tainan, Taiwan | 2019-10-01 |
Immunotherapy for HCC – What’s next? | Bristol-Myers Squibb Satellite Symposium in HCC: Bangkok | 2019-10-01 |
Neuroendocrine Tumor Treatment Development in Asia | The Second HUAXIA Oncology Summit Forum, Beijing, China | 2019-10-01 |
Defining the Right Treatment for the Right Patients: the perspective in Asian HCC treatment and HK experiences | Ipsen Kaoshiung Launch Symposium, Kaoshiung, Taiwan | 2019-10-01 |
Emerging Clinical Data with Immuno-oncology for HCC | Bristol-Myers Squibb Satellite Symposium in HCC: Hong Kong | 2019-10-01 |
Immunotherapy in the Management of Advanced HCC | Hong Kong Liver and Gastrointestinal Cancer Foundation HCC Masterclass 2019, Hong Kong | 2019-09-01 |
CheckMate-459 and KN 240 | Ipsen Global HCC Advisory board Meeting, Barcelona, Spain | 2019-09-01 |
The Future of First-Line Treatment of Advanced HCC: CheckMate-459 | MSD Global HCC Advisory board Meeting, Barcelona, Spain | 2019-09-01 |
Reappraisal of CheckMate-459 | Bayer Global HCC Advisory board Meeting, Barcelona, Spain | 2019-09-01 |
Reappraisal of CheckMate-459 and Managing Adverse Events with Immune Checkpoint Inhibitors | COSMIC 312 Investigator Meeting in ESMO 2019, Barcelona, Spain | 2019-09-01 |
Immunotherapy and Combinations in the Management of Advanced HCC | The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Hokkaido, Japan | 2019-08-01 |
Hong Kong Liver Cancer Staging | The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Hokkaido, Japan | 2019-08-01 |
Critical Updates on Hepatocellular Carcinoma from ASCO 2019 | BMS Morning Tea Symposium in Best of ASCO Asia and Singapore Congress 2019, Singapore | 2019-07-01 |
Updates on Immunotherapy in the Treatment of HCC | BMS Update on Immunotherapy in the Treatment of Hepatocellular Carcinoma, Singapore | 2019-07-01 |
HCC: Optimising Use of Immunotherapy and Managing IO Toxicities | BMS Lunch Symposium in Best of ASCO Asia and Singapore Congress 2019, Singapore | 2019-07-01 |
The Evolving Landscape of Immunotherapy-Based Combinations in Hepatocellular Carcinoma - What Should We Be Considering? | Taiwan Liver Cancer Association, 2019 Post-ASCO Highlight and Real World Data Review, Kaohsiung, Taiwan | 2019-07-01 |
The Evolving Landscape of Immunotherapy-Based Combinations in Hepatocellular Carcinoma - What Should We Be Considering | Taiwan Oncology Association, 2019 Post-ASCO meeting, Taipei Taiwan | 2019-07-01 |
Immune-related Adverse Event Management Algorithms | AstraZeneca EMERALD-1 Investigators’ Meeting, New Orleans, USA | 2019-06-01 |
Portending the future: How will a positive 1st line trial with check-point inhibitors in HCC change the treatment paradigm in HCC | 6th Asia Pacific Gastroenterology Cancer Summit 2019, Singapore | 2019-05-01 |
Updates on Immunotherapy in HCC | 3rd Singapore Liver Cancer Consortium (SLCC) Symposium Programme, Singapore | 2019-05-01 |
Real-world Experience with Cabozantinib | Ipsen HCC Asia Scientific Meeting, Seoul, South Korea | 2019-05-01 |
Checkpoint Inhibitors and Tyrosine Inhibitors Post Immunotherapy in the Management of Advanced HCC | Ipsen HCC Asia Scientific Meeting, Seoul, South Korea | 2019-05-01 |
Immune Checkpoint Inhibitor for Hepatocellular Carcinoma | Multi-specialty Medical Mega Conference, Hong Kong | 2019-04-01 |
The Use of Cabozantinib in Advanced HCC: CELESTIAL Experiences | Ipsen Expert Panel Meeting in Hepatocellular Carcinoma, Hong Kong | 2019-03-01 |
Taking a Leap Forward in Advanced Hepatocellular Carcinoma | Research Meeting, CStone Pharmaceuticals, Shanghai, China | 2019-03-01 |
Immunotherapy in Advanced Hepatocellular Carcinoma | MSD HCC Regional Expert Input Forum, Shanghai, China | 2019-03-01 |
Development of Immunotherapy in Hepatocellular Carcinoma Patients | Bristol-Myers Squibb Satellite Symposium in HCC, Macau | 2019-03-01 |
Treating Hepatocellular Carcinoma: A Fight Against the Odds | Bristol-Myers Squibb Satellite Symposium in HCC, Bangkok, Thailand | 2019-03-01 |
Neuroendocrine Tumor Treatment Development in Asia | The 2st Asian NET Expert Meeting, Taipei, Taiwan | 2019-02-01 |
Early Clinical Trials in Hong Kong (Oncology)-Opportunities & Challenges | Phase 1 Centre, West Hospital, Chengdu, China | 2019-02-01 |
Development of Immunotherapy in Hepatocellular Carcinoma Patients | 4th International Hepatobiliary & Pancreatic Diseases Summit Forum, Hangzhou, China | 2018-12-01 |
Taking a Leap Forward: What is the Latest Evidence of Systemic Therapy in Advanced Hepatocellular Carcinoma? | 26th Annual Scientific Meeting of Hong Kong College of Radiologists, Hong Kong | 2018-11-01 |
Poster presentation: PD-L1 expression in patients with anaplastic thyroid carcinoma: prevalence and outcome | Thyroid ISSN: 1050-7256 ; eISSN: 1557-9077 | 2018-10-01 |
Immunotherapy in Hepatocellular and Pancreatic Cancer: Hong Kong Experiences | First Oncology Forum, Shulan Hospital, Hangzhou, China | 2018-10-01 |
What Are The Latest Advances in Hepatobiliary and Pancreatic Cancers in 2018? | Hepatobiliary Meeting, Hong Kong Sanatorium & Hospital, Hong Kong | 2018-09-01 |
What is the role for cabozantinib as a new option in second-line aHCC? | 1st Ipsen Asia-Pacific Advisory Board in Hepatocellular Carcinoma, Seoul, Korea | 2018-07-01 |
Immunotherapy in HCC – a paradigm change | Fifth Asia Pacific Gastroenterology Cancer Summit 2018, Singapore | 2018-05-01 |
Approaches to Clinical Cases | The 1st Asian NET Expert Meeting, Incheon, South Korea | 2018-04-01 |
Immunotherapy for Advanced Hepatocellular Carcinoma: At the Dawn of a New Era | 2nd Singapore Liver Cancer Consortium (SLCC) Symposium Programme, Singapore | 2018-04-01 |
HK Real life Use of Sorafenib in HCC and How to Apply NexST sequence in Clinical Practice | Bayer HCC Stivarga HCC launch symposium—Optimal use of Systemic Therapy, Hong Kong | 2018-04-01 |
New Era of Systemic Therapy in unresectable HCC: Insights from RESORCE Study | Bayer Asia Pacific Hepatocellular Carcinoma Round Table Discussion, Macau | 2018-03-01 |
Evolving Landscape in unresectable HCC | Bayer Asia Pacific Hepatocellular Carcinoma Advisory Board, ChiangMai, Thailand | 2018-02-01 |
Updates in the Management of Refractory Colorectal Cancer | Bayer Macau Colorectal Cancer Round Table Discussion, Macau | 2018-01-01 |
Advances in the Management of Advanced Pancreatic Cancer | Zhejiang University International Hospital, Hangzhou, China | 2017-12-01 |
Recent Advances in Targeted Therapy in Soft Tissue Sarcoma | Pre-course Symposium: Precision Medicine in Sarcoma, 1st HKU International Musculoskeletal Tumour Course, Hong Kong | 2017-11-01 |
Cancer Immunotherapy: Recent Advances and Impact on Survival | 1st HKU International Musculoskeletal Tumour Course, Hong Kong | 2017-11-01 |
Checkpoint Inhibitors: Taking Off the Brakes in Immune System | State key Laboratory for Liver Research Symposium 2017, Hong Kong | 2017-11-01 |
Phase I trial of Recombinant Human Arginase 1 (PEG-BCT-100) combined with Capecitabine and Oxaliplatin (PACOX) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma | Symposium of Pegylated Human Recombinant Arginase in the Treatment of Cancers and other human Disease, Hong Kong | 2017-09-01 |
Immunotherapy for Pancreatic Cancer: Are We There Yet? | Asia Pacific Digestive Week 2017, Hong Kong | 2017-09-01 |
Immune Checkpoint Inhibitors in HCC | 2017 Seoul Liver Symposium, Seoul, South Korea | 2017-09-01 |
Debate: The Immune System is the Final Answer for against HCC | Liver Cancer ISSN: 2235-1795 ; eISSN: 1664-5553 | 2017-07-01 |
Hong Kong Liver Cancer Staging | 53rd Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan | 2017-07-01 |
The Role of Anti-EGFR and Tumor Location in 1st line Treatment of Metastatic Colorectal Cancer | The Oncology Symposium on mCRC Management, Ho Chi Minh City, Vietnam | 2017-07-01 |
Latest Advances in the Management of Advanced Hepatocellular Carcinoma | Novartis APECHO meeting, Shanghai, China | 2017-06-01 |
Management of Advanced Hepatocellular Carcinoma: At the Dawn of a New Era | Bristol-Myers Squibb Satellite Symposium in Inaugural Hong Kong International Oncology Forum, Hong Kong | 2017-05-01 |
Advances in the Management of Hepatocellular Carcinoma | Bayer Advisory Board Meeting, Hong Kong | 2017-05-01 |
Latest Advances in the Management of Advanced Hepatocellular Carcinoma | Hong Kong Medical Forum 2017 , Hong Kong | 2017-05-01 |
Chemotherapy and Adjuvant Chemotherapy for Colorectal Cancer | Symposium on Updates on Management of Colorectal Cancer organized by Ho Chi Minh city Medical University Hospital, Ho Chi Minh City, Vietnam | 2017-05-01 |
Immunotherapy in Advanced Hepatocellular Carcinoma | Zhejiang University International Hospital, Hangzhou, China | 2017-04-01 |
Emerging Therapies for Advanced Pancreatic Cancer Patients | Multi-specialty Medical Mega Conference, Hong Kong | 2017-04-01 |
The Updates about Immune Checkpoint Inhibitor in Advanced HCC | 5th Hong Kong Pathology Forum, Hong Kong | 2017-02-01 |
Management of Advanced Colorectal Cancer in Hong Kong | TaiHo Oncology Asia Colorectal Cancer Advisory Board, Singapore | 2016-12-01 |
Drug Development in Hepatocellular Carcinoma: Where are We in Asia | 3rd International Conference on Phase 1 and Early Phase Clinical Trials, Hong Kong | 2016-11-01 |
Medical Management of Lung NETs | 4th Asia Pacific Neuroendocrine Tumour Society Meeting, Penang, Malaysia | 2016-10-01 |
Cytotoxic & Targeted Therapies for GEP-NETs | 4th Asia Pacific Neuroendocrine Tumour Society Meeting , Penang, Malaysia | 2016-10-01 |
Biological Therapy in Hepatocellular Carcinoma | Bayer Metastatic Colorectal Cancer Advisory Board, Shanghai, China | 2016-10-01 |
Biological Therapy in Hepatocellular Carcinoma | Chinese Society of Hepatology Annual Meeting, Beijing, China | 2016-10-01 |
Optimizing the Sequential Treatment of 3L Metastatic Colorectal Cancer | Bayer Macau Satellite Symposium, Macau | 2016-09-01 |
The Clinical Guidelines Evolution in HCC from BCLC to HKLC - Where Does cTACE Fit In? | Gubert Satellite Symposium in Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), Hong Kong | 2016-07-01 |
Immunotherapy for Hepacellular Carcinoma---Are We Ready for the Prime Time? | Bristol-Myers Squibb Satellite Symposium in Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE), Hong Kong | 2016-07-01 |
Hong Kong Liver Cancer Staging | Plenary Session in 52nd Annual Meeting of Liver Cancer Study Group of Japan, Tokyo, Japan | 2016-07-01 |
How Emerging Molecular Genomics can Help to Improve the Survival of Patients with Colorectal Cancer? | 12th Shanghai International Colorectal Conference, Shanghai, China | 2016-06-01 |
Updated Treatment Options in Triple Negative Breast Cancer | 1st South East Asian Breast Cancer Symposium, Hue City, Vietnam | 2016-06-01 |
Immuno-Oncology in mCRC treatment: IgG1 vs. IgG2 | Department of Surgery, Linkou Chang Gung Memorial Hospital, Taipei, Taiwan | 2016-05-01 |
New Perspectives on Managing Progressive mCRC: In the Era of Angiogenesis | Sanofi-Aventis Macau Satellite Symposium, Macau | 2016-05-01 |
Management of Advanced Colorectal Cancer In the Era of Immunotherapy | The 21st Taiwan Joint Cancer Conference, Taipei, Taiwan | 2016-05-01 |
Immunotherapy in mCRC treatment | Department of Surgery, Tri-Service General Hospital is a medical center in Zhongzheng District, Taipei, Taiwan | 2016-05-01 |
Immuno-oncology in current targeted therapy of mCRC treatment | Taiwan Merck Serono Forum, Changhua, Taiwan | 2016-05-01 |
Immune Checkpoint Treatment in Hepatocellular Carcinoma | Multi-specialty Medical Mega Conference Sixth Round, Hong Kong | 2016-04-01 |
What Do we Do for Pancreatic Neuroendocrine Tumour in 2016 | Third Asia Pacific Gastroenterology Cancer Summit 2016, Bangkok, Thailand | 2016-04-01 |
Hepatocellular Carcinoma: Why aren’t We Making Progress with Systemic Treatment and What is the role of Ablative Strategies? | ESMO Asia 2015, Singapore | 2015-12-01 |
Advances in the Management of Hepatocellular Carcinoma | International Oncology Summit, Hangzhou, China | 2015-12-01 |
Treatment stratification for patients with hepatocellular carcinoma according to HCC stage | Asian Pacific Digestive Week 2015, Taipei, Taiwan | 2015-12-01 |
Epidemiology and Standard of care for Colorectal Cancer in Asia Pacific | Expert Input Forum for Pembrolizumab(Biomarker Development), Tokyo, Japan | 2015-11-01 |
Staging of Hepatocellular Carcinoma: Hong Kong vs Barcelona | 28th Annual Scientific Meeting, Hong Kong Association for the Study of Liver Diseases, Hong Kong | 2015-11-01 |
Optimizing mCRC treatment with Regorafnib: Personalised Dosing and AE management | Macau Oncology Association, Macau | 2015-11-01 |
Examining the Current evidence for Treatment of NET: Clinical Insights | Philippine Society of Medical Oncology Annual Conference 2015, Manila, Philippine | 2015-10-01 |
Hong Kong Liver Cancer Staging System | 2015 Seoul Liver Symposium, Seoul National University, Seoul, South Korea | 2015-10-01 |
Targeted Therapy in the Management of Advanced Colorectal Cancer | Novartis APECHO Meeting, Taipei, Taiwan | 2015-10-01 |
Hong Kong Liver Cancer Classification | The 7th Annual meeting of Asia Pacific Alliance of Liver Diseases, Qingdao, China | 2015-09-01 |
New Perspectives in Cancer Therapy - Immunotherapy | Macau Oncology Association, Macau | 2015-07-01 |
Future Perspectives in Breast Cancer Management | 2015 Latest Updates in Breast Cancer Management, Hong Kong Breast Cancer Foundation, Hong Kong | 2015-06-01 |
The Budding of Early Phase Oncology Drug Development Program in Asia: The University of Hong Kong Experiences | Princess Margaret Hospital, University of Toronto, Toronto, Canada | 2015-05-01 |
Staging and Guidelines for HCC: NCCN, Barcelona or Hong Kong | World Congress of Interventional Oncology (WCIO) 2015, New York, United States | 2015-05-01 |
Staging System for Hepatocellular Carcinoma: How Should it Affect the Management | 5th Asia-Pacific Hepato-Pancreato-Biliary Association Meeting, Singapore | 2015-03-01 |
Optimal Staging System for Hepatocellular Carcinoma: Hong Kong versus Barcelona | The 9th Korean Cancer Study Group Symposium, Seoul, South Korea | 2015-02-01 |
Hepatitis C Infection and Hepatocellular Carcinoma | Second Chinternational Hepatitis C Forum, Hong Kong | 2015-02-01 |
Optimizing patient outcomes in mCRC – Does CONCUR CORRECT-ly concur? | Bayer Malaysia Satellite Symposium, Kuala Lumpur, Malaysia | 2015-01-01 |
Novel Therapies for Advanced Colorectal Cancer | Penang General Hospital Oncology CME Lecture, Penang, Malaysia | 2015-01-01 |
Targeted Therapies For Esophageal and Gastric Cancer | MAGICS (Multi-national Alliant Gastro-Intestinal Cancer Symposium) 2015, Seoul, South Korea | 2015-01-01 |
Future Perspective in the Management of metastatic CRC | CME Lecture, National Cancer Institute (Institut Kanser Negara-IKN), Kuala Lumpur, Malaysia | 2015-01-01 |
Emerging Therapies for Advanced Pancreatic Cancer Patients | IASGO World Congress 2014, Vienna, Austria | 2014-12-01 |
Debate Advanced G2 NET: Case for TKIs | 2nd Asia Pacific Neuroendocrine Tumour Society Meeting, Kochi, India | 2014-11-01 |
Systemic Treatment in HCC: Is There Light at the End of the Tunnel? | Asia Pacific Gastroenterology Cancer Summit 2014, Singapore | 2014-11-01 |
The modern management of treatment refractory advanced colorectal cancer patients – The Asian Perspective | CME meeting, Department of Oncology, University of Malaya, Kuala Lumpur, Malaysia | 2014-11-01 |
The Treatment Algorithm for Refractory Colorectal Cancer | Bayer Singapore and Malaysia Regorafenib Advisory Board Meeting, Singapore | 2014-11-01 |
Does CONCUR CORRECT-ly concur in treatment settings of mCRC – The Asian Perspective | Research Meeting, Department of Medicine, National University Hospital of Singapore, Singapore | 2014-11-01 |
Does CONCUR CORRECT-ly concur in treatment settings of mCRC – The Asian Perspective | Asia Pacific Gastroenterology Cancer Summit 2014 Bayer Tea Symposium, Singapore | 2014-11-01 |
Neoadjuvant Therapy for Neuroendocrine Tumours | 2nd Asia Pacific Neuroendocrine Tumour Society Meeting, Kochi, India | 2014-11-01 |
The Use of Chemotherapy in Pregnancy | Maternal Fetal Medicine Postgraduate Meeting, Queen Elizabeth Hospital, Hong Kong | 2014-10-01 |
Drug Development for Advanced Hepatocellular Carcinoma | Hong Kong Sanatorium Hospital Tumour Board Meeting, Hong Kong | 2014-10-01 |
Staging for Hepatocellular Carcinoma: Hong Kong versus Barcelona | States Key Laboratory of Liver Research Symposium 2014, Hong Kong | 2014-09-01 |
Latest biomarker developments for EGFR inhibitors in mCRC - An Update from Medical Oncologist’s Perspective | Ras Expert Forum | 2014-08-01 |
Defining the boundary between surgery and TACE | The 5th Asia-Pacific Primary Liver Cancer Meeting | 2014-07-01 |
Role of targeted therapies in the management of mCRC beyond progression & local experience sharing | Asia-Pacific Oncology Conference | 2014-07-01 |
Medical Oncology News in Breast Cancer 2014 | Updates in Breast Cancer Management | 2014-07-01 |
Therapeutic Advances in the Systemic Therapy of Hepatocellular Carcinoma | International Congress and the Third IASGO CME Postgraduate Course | 2014-06-01 |
Neoadjuvant therapy of Advanced Pancreatic Cancer: Dream or Fallacy | Hong Kong Sanatorium Hospital Tumour Board Meeting | 2014-05-01 |
Management of Ras Wild Type Metastatic Colorectal Cancer | GlaxoSmithKline Vertibix Launch Symposium | 2014-04-01 |
Treatment for Refractory Colorectal Cancer: Any Hope in 2014? | Asian Oncology Summit 2014 | 2014-04-01 |
New Drug Development for Advanced Hepatocellular Carcinoma | Asian Oncology Summit 2014 | 2014-04-01 |
Contemporary Strategies for Battling Breast Cancer D2 Summary | Eisai Symposium of Comtemporary Oncology 2014 | 2014-02-01 |
New Perspective in the Targeted Therapy of Advanced Colorectal Cancer | Hong Kong Pathology Forum | 2014-01-01 |
Abraxane-An Overview of Clinical Efficacy | Celgene East Asia Clinical Management Meeting | 2014-01-01 |
San Antonio Updates of Breast Cancer 2013 | Novartis San Antonio Breast Cancer Update Meeting | 2014-01-01 |
45 Years Old Gentleman with Pancreatic Neuroendocrine Tumour:
Advances in the Therapeutic Options | Asia-Pacific Gastroenterology Cancer Summit 2013 | 2013-12-01 |
Novel Targeted Therapies in the Management of Hepatocellular Carcinoma | Asia-Pacific Gastroenterology Cancer Summit 2013 | 2013-12-01 |
Perspectives in Multidisciplinary Team Management of Metastatic Colorectal Cancer | The 11th Asia Pacific Congress of Endoscopic and Laparoscopic Surgery | 2013-11-01 |
Molecular Therapy of NETs | Inaugural Conference of The Asia Pacific Neuroendocrine Tumour Society | 2013-10-01 |
Review of metastatic hepatocellular carcinoma | Genectech GO28651 Investigator Meeting, Hong Kong | 2013-07-01 |
Preemptive treatment for patients on chemotherapy to prevent hepatitis B reactivation | Annual Scientific Meeting of Macau Society of Gastroenterology & Hepatology, Macau, 13-14 July 2013 | 2013-07-01 |
Preemptive treatment for patients on chemotherapy to prevent hepatitis B reactivation | Novartis Evening Satellite Symposium, Macau | 2013-07-01 |
New horizons in the management of chemotherapy refractory advanced colorectal cancer | Hospital Universiti Sains Malaysia Oncology CME Lecture, Kota Bharu, Malaysia | 2013-06-01 |
Novel loco-regional therapies for advanced colorectal cancer with liver involvement | 9th Shanghai International Colorectal Conference, Shanghai, China | 2013-06-01 |
Targeted therapy for hepatocellular carcinoma: from bench to bedside | The 10th Liver Update 2013, Malaysia Liver Cancer Foundation, Kuala Lumpur, Malaysia, 20-23 June 2013 | 2013-06-01 |
Changing paradigm of metastatic colorectal cancer management in year 2013 | Singapore Bayer Schering Colorectal Experts Round Table Lunch Symposium, Singapore | 2013-06-01 |
Recent advances and future directions in the targeted therapy in solid tumours | The Hong Kong Alumni Association Sun Yat Sen University of Medical Sciences | 2013-04-01 |
Systemic management of hepatocellular carcinoma and pancreatic cancer | Central Pharmacy Office, Hong Kong Hospital Authority, Hong Kong | 2013-03-01 |
Systemic treatment of metastatic neuroendocrine tumours to the liver | The 4th Biennial Congress of the Asia-Pacific Hepato-Pancreato-Biliary Association, Shanghai, China, 27-30 March 2013 | 2013-03-01 |
Local-regional therapy for colorectal liver metastases | The 4th Biennial Congress of the Asia-Pacific Hepato-Pancreato-Biliary Association, Shanghai, China, 27-30 March 2013 | 2013-03-01 |
Evolution in the systemic therapy of advanced pancreatic cancer | Hong Kong Sanatorium Hospital Tumour Board Meeting, Hong Kong | 2012-11-01 |
Molecular targeted therapy of advanced hepatocellular carcinoma | State Key Laboratory of Liver Diseases Shanghai Meeting, Shanghai, China | 2012-10-01 |
Latest advances in the management of advanced hepatocellular carcinoma | Macau Oncology Association Oncology Symposium, Macau | 2012-09-01 |
Evidence based sorafenib use in Asian population: benefits in elderly and Child Pugh B population | Asia-Pacific Bayer Expert Symposium on Targeted Therapies (AP BEST), Ho Chi Minh City, Vietnam | 2012-08-01 |
Management of advanced colorectal cancer: case by case discussion | The 3rd Oncology Forum, Hong Kong | 2012-07-01 |
The use of SECOX (Sorafenib, Oxaliplatin, Capecitabine) as the treatment of advanced hepatocellular carcinoma (HCC): a single center experience | The 10th Annual Meeting of the Japanese Society of Medical Oncology, Osaka, Japan, 26-28 July 2012 | 2012-07-01 |
Hepatobiliary research highlight and future direction in Hong Kong | United States National Cancer Institue (NCI) Hepatobiliary Task Force Meeting, Chicago, USA | 2012-06-01 |
Molecular targeted therapies of common cancers | The Association of Licentiates of Medical Council of Hong Kong CME Lecture, Hong Kong | 2012-06-01 |
Systemic therapy of advanced hepatocellular carcinoma in the era of personalized medicine: Asian perspective | Princess Margaret Hospital, University of Toronto, Toronto, Canada | 2012-05-05 |
Metastatic colorectal cancer - facts (Epidemiology & treatment standards) | The 3rd Merck Serono Asian Oncology Summit, Hong Kong | 2012-05-03 |
Clinical utility of genomic profiling in making adjuvant treatment decisions in node-positive early breast cancer | Hong Kong Society of Breast Surgeons and Hong Kong Breast Cancer Foundation CME Lecture, Hong Kong | 2012-05-01 |
Systemic therapy of advanced hepatocellular carcinoma: medical oncologist perspectives | Macau Peak Hospital, Macau | 2012-04-02 |
Systemic management of hepatocellular carcinoma and pancreatic cancers: medical oncologist perspectives | CME Lecture of Private Service and Department of Clinical Oncology, Queen Mary Hospital, Hong Kong | 2012-04-01 |
Systemic therapy of advanced hepatocellular carcinoma: are we making progress in the era of personalized medicine? | University College of London Cancer Institute, University of London, UK | 2012-03-03 |
Practical applications of anti-angiogenic agents in systemic management of hepatocellular carcinoma | Department of Medicine Grand Round, Kwong Wah Hospital, Hong Kong | 2012-03-01 |
GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) second interim analysis in >1500 patients: clinical findings in patients with liver dysfunction | The 4th Singapore Society of Oncology & Chapter of Medical Oncologists Review Course, Bayer Tea Symposium, Singapore | 2012-02-05 |
Practical applications of anti-angiogenic therapy in unresectable hepatocellular carcinoma | The 4th Singapore Society of Oncology & Chapter of Medical Oncologists Review Course, Singaore | 2012-02-04 |
Practical applications of targeted therapy in systemic management of hepatocellular carcinoma | Singapore Bayer Schering Round Table Symposium, Singapore | 2012-02-01 |
Management of refractory colorectal cancer: what is on the horizon? | The 18th Hong Kong International Cancer Congress, The University of Hong Kong, Hong Kong | 2011-11-03 |
The use of Sorafenib in the mnagement of advanced hepatocellular carcinoma: benefit in elderly patients? | Bayer Schering Asia Gideon Virtual Meeting, Singapore | 2011-10-03 |
The introduction to the management of neuroendocrine tumours | Novartis Asia-Pacific Neuroendocrine Tumour School, Hong Kong | 2011-10-02 |
Optimizing treatment for metastatic renal cell carcinoma | Macau Oncology Association Summer Symposium, Macau | 2011-08-30 |
The Asian perspectives in the management of K-Ras wild type advanced colorectal cancer: bevacizumab or anti-EGFR therapy? | Round Asia Oncology Forum, Chinese Society of Clinical Oncology, Shanghai, China | 2011-08-25 |
The systemic management of advanced hepatocellular carcinoma patients: are we making any progress in the era of personalised medicine? | Bit’s 1st Annual World Congress of Microbes, Beijing, China | 2011-08-01 |
Systemic therapy of advanced hepatocellular carcinoma in 2011 | Public Health Talk Organised by the Health Action, Hong Kong | 2011-07-31 |
Systemic therapy of advanced hepatocellular carcinoma beyond sorafenib | BIT’s 4th World Congress of Cancer, Dalian, China | 2011-05-22 |
Metastatic pancreatic neuroendocrine tumour patient with impressive tumour shrinkage with sunitinib | Pfizer Asia Pancreatic Neuroendocrine Tumour Advisory Board, Chengdu, China | 2011-03-01 |
Neoadjuvant therapy of locally advanced breast cancer in Asian population: reality or fantasy? | Hong Kong Sanatorium Hospital CME lecture, Hong Kong | 2011-03-01 |
Evolving standard of care: a novel antiangiogenic agent for treating metastatic renal cell carcinoma | Hong Kong Pharmacy Conference 2011, Hong Kong, China | 2011-02-01 |
The power of anti-angiogenic and m-TOR inhibitors in the management of advanced renal cell carcinoma | Asia Pacific Uro-oncology Summit, Kaohsiung, Taiwan | 2011-01-01 |
The synergy between anti-angiogenic and m-TOR inhibitors in the management of advanced renal cell carcinoma | Veterans General Hospital, Taichung, Taiwan | 2011-01-01 |
The use of anti-angiogenic and m-TOR inhibitors in the management of advanced renal cell carcinoma | Chang Gung Memorial Hospital, Taipei, Taiwan | 2011-01-01 |
The future of systemic therapy for advanced gastric cancer patients | Astra-ZeneCa Gastric Cancer Advisory Board, Tokyo, Japan | 2010-11-01 |
The experiences in using a c-Met inhibitor: foretinib in the management of advanced HCC patients at Queen Mary Hospital | Patient Enrollment and Management Workshop, GlaxoSmithKline Foretinib Investigator Meeting, Taipei, Taiwan | 2010-10-01 |
A man with aggressive advanced colorectal cancer | World Congress on Gastrointestinal Cancer: Asian Perspectives, Hong Kong, China | 2010-08-27 |
The power of targeted agents in the management of advanced RCC | 10th Asian Congress of Urology, Taipei, Taiwan | 2010-08-27 |
The management of cancer patients in the era of personalized medicine | Department of Medicine Grand Round, Kwong Wah Hospital, Hong Kong | 2010-08-01 |
The use of temsirolimus in treating advanced renal cell carcinoma patients | Pfizer Renal Cell Carcinoma Advisory Board, Taipei, Taiwan | 2010-08-01 |
Systemic therapy of advanced hepatocellular carcinoma: are we making progress in the era of personalized medicine? | Tucker Gosnell Centre for Gastrointestinal Cancer, Massachusetts General Hospital, Dana-Farber Cancer Centre, Harvard Medical School, USA | 2010-07-01 |
GOFURTGO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC) | Asian Oncology Summit, Bali, Indonesia | 2010-04-01 |
Recent advances in the targeted therapy of advanced hepatocellular carcinoma | Macau Peak Hospital, Macau | 2010-04-01 |
Nexavar: the reference standard in the management of hepatocellular carcinoma | Bayer-Schering Hepatocellular Carcinoma Satellite Symposium, Asian Oncology Summit, Bali, Indonesia | 2010-04-01 |
The future direction of advanced hepatocellular carcinoma research | Bayer-Schering Greater China BESTT Meeting, Chiang Mai, Thailand | 2010-03-01 |
The molecular therapy of advanced hepatocellular carcinoma in the era of targeted therapy | Second International Conference on Drug Discovery and Therapy, Dubai, UAE | 2010-02-01 |
The fundamentals in the management of advanced hepatocellular carcinoma | Liver Cancer Meeting, Bayer-Schering, Hong Kong | 2010-01-01 |
The new advances in the targeted therapy of advanced hepatocellular carcinoma | BIT’s 1st Annual International Congress of Antibodies, Beijing, China | 2009-05-01 |
The fundamentals and advances in the management of colorectal cancer | Colorectal Cancer Symposium, Roche Hong Kong Ltd, Hong Kong | 2009-03-01 |
The state-of-the-art treatment for advanced hepatocellular carcinoma | Hong Kong Chinese Civic Servant Society, Hong Kong | 2009-03-01 |
Phase II open label study of single agent sorafenib in treating advanced hepatocellular carcinoma in hepatitis-B endemic Asian population: presence of lung metastasis predicts poor response | 6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences, Soeul, Korea | 2008-12-01 |
Selectively high efficacy of bevacizumab-based chemotherapy for first-line palliation of advanced colorectal cancer in Chinese patients | Roche Asian Oncology Forum, Bangkok, Thailand | 2008-11-01 |
Latest advances in the treatment of advanced hepatocellular carcinoma | Macau Peak Hospital, Macau | 2008-09-01 |